Unfractionated Heparin Dosing for NSTEMI
For patients with NSTEMI, administer intravenous unfractionated heparin with a loading dose of 60 IU/kg (maximum 4000 IU) followed by a continuous infusion of 12 IU/kg/hour (maximum 1000 IU/hour), adjusted to maintain an aPTT of 60-80 seconds. 1
Initial Dosing Strategy
The 2025 ACC/AHA/ACEP/NAEMSP/SCAI guidelines provide the most current recommendations for UFH in NSTEMI patients 1:
- Loading dose: 60 IU/kg IV bolus (maximum 4000 IU)
- Maintenance infusion: 12 IU/kg/hour (maximum 1000 IU/hour)
- Target aPTT: 60-80 seconds (1.5-2 times normal)
This dosing applies to initial therapy before coronary angiography and should be initiated at the time of diagnosis 1. The FDA labeling confirms these weight-based parameters for therapeutic anticoagulation 2.
Monitoring Requirements
Check aPTT approximately every 4 hours initially, then at appropriate intervals once therapeutic range is achieved 2. The dosing is considered adequate when aPTT reaches 60-80 seconds. Additionally:
- Monitor baseline coagulation status (aPTT, INR, platelet count)
- Periodically check platelet counts, hematocrit, and occult blood in stool throughout therapy
- Adjust infusion rate based on aPTT results to maintain therapeutic range
Dosing During PCI
If the patient proceeds to PCI, additional UFH dosing depends on prior anticoagulation 1:
- If already receiving UFH: Give additional boluses as needed to achieve ACT 250-300 seconds
- If no prior anticoagulation: Give 70-100 U/kg initial bolus to achieve target ACT 250-300 seconds
The 2020 ESC guidelines similarly recommend weight-adjusted IV bolus of 70-100 IU/kg during PCI (or 50-70 IU/kg if combined with GP IIb/IIIa inhibitor), targeting ACT 250-350 seconds 3.
Duration of Therapy
Continue parenteral anticoagulation until revascularization is performed 1. Discontinue UFH immediately after PCI unless specific clinical circumstances require ongoing anticoagulation (e.g., LV thrombus, atrial fibrillation) 3.
Critical Dosing Considerations
Weight-Based Dosing is Essential
Research demonstrates that fixed dosing (e.g., standard 5000 U bolus, 1000 U/hour infusion) frequently results in excess weight-adjusted doses, particularly in elderly patients and women with lower body weight 4. Excess dosing above guideline recommendations (>70 U/kg bolus or >15 U/kg/hour infusion) is associated with increased major bleeding without improved efficacy 4.
Maximum Dose Caps
The 4000 IU maximum bolus and 1000 IU/hour maximum infusion are intentionally conservative to prevent overdosing in heavier patients 1, 2. Some evidence suggests higher maximum doses may achieve therapeutic anticoagulation faster without increased bleeding 5, but current guidelines maintain these conservative caps.
Obese Patients
Use total body weight for dosing calculations. Studies show that dosing based on either total body weight or adjusted body weight in obese patients (BMI ≥30 kg/m²) results in similar times to therapeutic anti-Xa levels and comparable safety outcomes 6.
Common Pitfalls to Avoid
- Do not use fixed dosing: Always calculate weight-based doses rather than defaulting to "standard" 5000 U bolus or 1000 U/hour infusion
- Do not crossover anticoagulants: Avoid switching between UFH and LMWH; if fondaparinux was used initially, add UFH at time of PCI rather than switching 1, 3
- Do not delay for elevated anti-Xa levels in DOAC users: If patient is on direct oral anticoagulants, elevated heparin anti-Xa assays are artifactual and should not delay UFH initiation; these levels normalize within 12 hours 7
- Do not continue infusion post-PCI: Discontinue immediately after procedure unless specific indication exists 3
Alternative Anticoagulants
While UFH is the standard and most widely used anticoagulant for NSTEMI 1, alternatives include:
- Enoxaparin or fondaparinux: Recommended alternatives if early invasive approach is not anticipated 1
- Bivalirudin: May be reasonable as alternative during PCI to reduce bleeding (Class 2b recommendation) 1, though recent meta-analysis shows no mortality difference and similar ischemic event rates compared to heparin 8
The 2025 guidelines give UFH a Class 1, Level B-R recommendation for reducing ischemic events in NSTEMI, making it the preferred initial anticoagulant strategy 1.